Search Result

Results for "

Sirtuin

" in MCE Product Catalog:

By Targets:	Sirtuin (24) Apoptosis (5) Autophagy (2) HBV (1) Histone Methyltransferase (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) Parasite (3) Phosphatase (2) Reverse Transcriptase (2) SARS-CoV (3) Topoisomerase (2)
By Research Areas:	Cancer (19) Cardiovascular Disease (7) Infection (5) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Targets Recommended: Sirtuin

Cat. No.	Product Name	Target	Research Areas

HY-Q49697

Sirtuin modulator 3

Sirtuin Cancer Metabolic Disease Inflammation/Immunology

Sirtuin modulator 3 (compound 129) is a N-phenyl benzamide derivative, acts as a sirtuin modulator.

Sirtuin modulator 3	Sirtuin	Cancer Metabolic Disease Inflammation/Immunology
Sirtuin modulator 3 (compound 129) is a N-phenyl benzamide derivative, acts as a *sirtuin* modulator.

HY-147234

Sirtuin modulator 2	Sirtuin	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease Cardiovascular Disease
Sirtuin modulator 2 (Compound 132) is a *sirtuin* modulator with an ED₅₀ equal or less than 50 μM.

HY-19758A

Sirtuin modulator 1

Sirtuin Cancer

Sirtuin modulator 1 is a modulator of SIRTl, a homolog of SIRT3, with EC_1.5 of < 1 μM, extracted from patent WO 2010071853 A1, Compound No.4.

Sirtuin modulator 1	Sirtuin	Cancer
Sirtuin modulator 1 is a modulator of SIRTl, a homolog of *SIRT3*, with EC_1.5 of < 1 μM, extracted from patent WO 2010071853 A1, Compound No.4.

HY-148322

Sirtuin modulator 5	Sirtuin	Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
Sirtuin modulator 5 is a *sirtuin* modulating agent. Sirtuin modulator 5 can activate *SIRT1* with a DC₅₀ value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity.

HY-148312

Sirtuin modulator 4	Sirtuin	Cancer Inflammation/Immunology Neurological Disease Cardiovascular Disease
Sirtuin modulator 4 (compound 12) is a *sirtuin* modulator. Sirtuin modulator 4 shows inhibitory effect to *SIRT1* with an EC₅₀ value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer.

HY-119857

AGK7 SIRT2 Inhibitor,Inactive Control	Sirtuin	Neurological Disease
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease.

HY-124113

4'-Bromo-resveratrol 4′‐BR	Sirtuin Apoptosis	Cancer
4'-Bromo-resveratrol is a potent and dual inhibitor *Sirtuin-1* and *Sirtuin-3*. 4'-Bromo-resveratrol inhibits melanoma cell growth through mitochondrial metabolic reprogramming. 4'-Bromo-resveratrol imparts antiproliferative effects in melanoma cells through a metabolic reprogramming and affecting the cell cycle and apoptosis signaling.

HY-155725

Z26395438

Sirtuin Others

Z26395438 (compound 1) is a potent Sirtuin-1 inhibitor, with an IC₅₀ value of 1.6 μM.

Z26395438	Sirtuin	Others
Z26395438 (compound 1) is a potent Sirtuin-1 inhibitor, with an IC₅₀ value of 1.6 μM.

HY-124037

SRT 1460 1 Publications Verification	Sirtuin	Cancer
SRT 1460, a potent **Sirtuin-1 (SIRT1) activator with an EC_1.5** value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues.

HY-112587

MC3482

3 Publications Verification

Sirtuin Cancer

MC3482 is a specific sirtuin5 (SIRT5) inhibitor.

MC3482 3 Publications Verification	Sirtuin	Cancer
MC3482 is a specific sirtuin5 (SIRT5) inhibitor.

HY-N2673

5-Heptadecylresorcinol 5-n-Heptadecylresorcinol; AR-C17	Sirtuin	Metabolic Disease Cardiovascular Disease
5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via *sirtuin3* signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity.

HY-19759

SRT 2183 2 Publications Verification	Sirtuin Apoptosis	Cancer
SRT 2183 is a selective **Sirtuin-1 (SIRT1) activator with an EC_1.5** value of 0.36 μM. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels.

HY-112634

SIRT5 inhibitor 1

4 Publications Verification

Sirtuin Others

SIRT5 inhibitor 1 is a potent Human Sirtuin 5 deacylase inhibitor, with an IC₅₀ of 0.11 μM.
HY-112427

Sirt2-IN-1

Sirtuin Cancer Inflammation/Immunology

Sirt2-IN-1 (Compound 9) is a sirtuin 2 (Sirt2) inhibitor with an IC₅₀ of 163 nM.

SIRT5 inhibitor 1 4 Publications Verification	Sirtuin	Others
SIRT5 inhibitor 1 is a potent Human Sirtuin 5 deacylase inhibitor, with an IC₅₀ of 0.11 μM.

Sirt2-IN-1	Sirtuin	Cancer Inflammation/Immunology
Sirt2-IN-1 (Compound 9) is a sirtuin 2 (Sirt2) inhibitor with an IC₅₀ of 163 nM.

HY-115453

UBCS039 5+ Cited Publications	Sirtuin Autophagy	Cancer
UBCS039 is the first synthetic, specific **Sirtuin 6 (SIRT6) activator, inducing autophagy in human tumor cells, with an EC₅₀** of 38 μM.

HY-118343

AC-93253

Sirtuin Cancer

AC-93253 is a selective, potent SIRT2 inhibitor. AC93253 can inhibit SIRT2 with an IC₅₀ value of 6 μM. AC93253 can be used for the research of tumors.
HY-108986

JFD00244

Sirtuin SARS-CoV Cancer

JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2.

AC-93253	Sirtuin	Cancer
AC-93253 is a selective, potent *SIRT2* inhibitor. AC93253 can inhibit SIRT2 with an IC₅₀ value of 6 μM. AC93253 can be used for the research of tumors.

JFD00244	Sirtuin SARS-CoV	Cancer
JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2.

HY-13515

Sirtinol Maximum Cited Publications 12 Publications Verification	Sirtuin Autophagy Apoptosis	Cancer
Sirtinol is a **sirtuin (SIRT) inhibitor, with IC₅₀**s of 48 μM, 57.7 μM and 131 μM for ySir2, hSIRT2 and hSIRT2, respectively.

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Cancer Cardiovascular Disease
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and **Sirtuin 1 (Sirt1)** in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research.

HY-107453

SirReal1-O-propargyl PROTAC Sirt2-binding moiety 1	Ligands for Target Protein for PROTAC	Cancer
SirReal1-O-propargyl is a selective and highly potent **Sirtuin 2 (Sirt2) inhibitor, with an IC₅₀** of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2.

HY-107454

OSS_128167 10+ Cited Publications	Sirtuin HBV	Cancer Infection Metabolic Disease Inflammation/Immunology
OSS_128167 is a potent selective **sirtuin 6 (SIRT6) inhibitor with IC₅₀s of 89 μM, 1578 μM and 751 μM for SIRT6*, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV* activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects.

HY-117006

E1231 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with *SIRT1* (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases.

HY-W020111

7-Chloro-4-(piperazin-1-yl)quinoline	Sirtuin Parasite	Infection
7-Chloro-4-(piperazin-1-yl)quinolone is an important scaffold in medicinal chemistry. 7-Chloro-4-(piperazin-1-yl)quinolone is a potent *sirtuin* inhibitor and also inhibits the serotonin uptake (IC₅₀ of 50 μM). 7-Chloro-4-(piperazin-1-yl)quinolone exhibits antimalarial activity on D10 and K1 strains of *P. falciparum* with IC₅₀s of 1.18 μM and 0.97 μM, respectively.

HY-B0879A

Suramin sodium salt 10+ Cited Publications Suramin hexasodium salt	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Cancer Infection Cardiovascular Disease
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin sodium salt is a potent inhibitor of *sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM). Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM). Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)* inhibitor. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.

HY-B0879

Suramin 10+ Cited Publications	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Cancer Infection Cardiovascular Disease
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin is a potent inhibitor of *sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM). Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM). Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)* inhibitor.Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library	546 compounds
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases. MCE owns a unique collection of 546 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Histone Modification Research Compound Library

546 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 546 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L034

Anti-Aging Compound Library	3867 compounds
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 3867 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Anti-Aging Compound Library

3867 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 3867 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

HY-L037

Antioxidant Compound Library	1303 compounds
Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer. MCE Antioxidant Compound Library contains 1303 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

Antioxidant Compound Library

1303 compounds

Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.

MCE Antioxidant Compound Library contains 1303 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

Cat. No.	Product Name	Target	Category